Macrogenics (FRA:M55) Moat Score: 5/10 (As of Jul. 09, 2026)


FRA:M55 Macrogenics Inc FRA:M55
47 GF Score
Price €4.12
GF Value €3.59
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Macrogenics Moat Score?

Macrogenics FRA:M55 +4.04% 47 Moat Score is 5 as of Jul. 09, 2026. GuruFocus rates FRA:M55 with a GF Score™ of 47/100 and a GF Value™ of €3.59 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 1,394 Biotechnology companies, Macrogenics ranks better than 96.7% on this metric.

Macrogenics has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

Macrogenics has Narrow Moat: Macrogenics Inc has a solid narrow moat due to its valuable intellectual property and R&D capabilities in biotechnology. However, it faces significant competition and lacks strong market leadership or brand strength.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Macrogenics might have Narrow Moat - Solid narrow moat.

Macrogenics  (FRA:M55) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Macrogenics Moat Score Related Terms

FRA:M55 vs IMRX, TRDA, SLNCF: Moat Score Comparison

For the Biotechnology subindustry, Macrogenics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macrogenics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Moat Score distribution charts can be found below:

* The bar in red indicates where Macrogenics's Moat Score falls into.


FRA:M55
47GF Score
Macrogenics Inc FRA:M55
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
Macrogenics (FRA:M55) has a Moat Score of 5 as of Jul. 09, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Macrogenics ranks #46 out of 1394 companies in the Biotechnology industry, placing it in the top 3.3%.
Is Macrogenics' Moat Score too high?
Macrogenics' current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. Macrogenics' value of 5 is 150% above this industry median. Based on the distribution chart, Macrogenics ranks #46 out of 1394 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Moat Score compare to IMRX and TRDA?
According to the Biotechnology industry distribution chart, Macrogenics ranks #46 out of 1394 companies for Moat Score. This places Macrogenics in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Macrogenics' value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Macrogenics's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Macrogenics's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (FRA:M55) is currently considered Modestly Overvalued. The stock's GF Value™ is €3.59, compared to a current price of €4.12 — trading 14.8% above its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Macrogenics (FRA:M55), the current Moat Score is 5 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (FRA:M55) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of €4.12 is trading 14.8% above its estimated GF Value™ of €3.59. GuruFocus considers Macrogenics to be Modestly Overvalued.

Key valuation signals for FRA:M55:

  • Moat Score: 5
  • GF Value™: €3.59 vs. price of €4.12 (14.8% above fair value)
  • GF Score™: 47/100 with 8 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1394)

No single metric tells the full story. See the FRA:M55 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Macrogenics Business Description

Other Exchanges MGNX:USA
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score

Get the complete analysis for FRA:M55

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.12
Price
€3.59
GF Value